Mechanism of Action
CRF2 Receptor Selectivity
CRF2 is a Gs-coupled GPCR expressed in lateral septum, raphe nuclei, bed nucleus of stria terminalis, amygdala, heart, and GI tract. Stresscopin binds CRF2 with >100-fold selectivity over CRF1, making it the ideal research tool for parsing CRF2-specific effects. cAMP signaling via CRF2 in the lateral septum and raphe produces anxiolytic, anti-fear, and feeding-suppressive effects distinct from the anxiogenic and HPA-activating effects of CRF1.
Stress Recovery and Homeostasis
While CRH/CRF1 initiates the stress response (acth/" class="wiki-internal-link">ACTH, cortisol, anxiety), UCN3/CRF2 in lateral septum and bed nucleus of stria terminalis promotes the resolution and recovery phase by: dampening amygdala fear output, reducing sympathetic tone, suppressing appetite after acute stress, and normalizing cardiovascular parameters. This temporal sequence of CRF1 (stress initiation) then CRF2 (stress recovery) organizes the complete stress arc.
Research Summary
Anxiety and PTSD
Active ResearchICV UCN3 (stresscopin) produces anxiolytic effects in rat elevated plus-maze and fear extinction paradigms. CRF2 knockout mice show exaggerated anxiety responses and impaired fear extinction. UCN3 signaling in the medial amygdala reduces fear expression via lateral septum projections. CRF2 agonists are explored as novel anxiolytics and PTSD adjuvants without the abuse potential of benzodiazepines.
Metabolic and Appetite Effects
Active ResearchStresscopin reduces food intake in rodents via CRF2 receptors in VMH and brainstem. CRF2 in pancreatic beta cells modulates insulin secretion in response to stress hormones. UCN3-expressing neurons project from hypothalamus to pancreatic islets, forming a neuroendocrine axis that coordinates stress responses with metabolic function.
Cardiac Function
Active ResearchCRF2 receptors on cardiomyocytes and coronary vasculature mediate UCN3-induced positive inotropy and coronary vasodilation. IV UCN3 improves cardiac output in heart failure models without the tachycardia associated with beta-adrenergic agents. CRF2 cardiac agonism represents a potentially novel inotropic mechanism.
Calculate your Stresscopin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Anxiety/stress research | 0.1-1 nmol ICV in rodent anxiety models | Per session | ICV |
| Feeding/metabolic research | 0.3-3 nmol ICV or 5-30 nmol/kg IP | Per session | ICV or intraperitoneal |
Research tool for CRF2-specific studies. Distinguish from astressin2-B (CRF2 antagonist) used to block CRF2 signaling. No human therapeutic development currently.
Interactions
Safety Profile
No human safety data. Research doses in animals produce anxiolysis, appetite suppression, and increased cardiac output -- expected pharmacological effects. No significant toxicity reported in preclinical studies. CRF2 receptor distribution is more limited than CRF1, potentially providing a more targeted side effect profile than non-selective CRH ligands. Systemic CRF2 activation may affect cardiovascular tone and GI motility based on peripheral receptor expression.
References
- [1]Lewis K, et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA. 2001;98(13):7570-7575.
- [2]Risbrough VB, et al. Role of corticotropin releasing factor (CRF) receptors 1 and 2 in fear and anxiety. Behav Pharmacol. 2003;14(2):163-170.